(Q40359978)

19 September 2017

title

A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors (English)

1 reference

19 September 2017

Yasuhito Fujisaka

1

1 reference

19 September 2017

Yasuhide Yamada

2

1 reference

19 September 2017

Noboru Yamamoto

3

1 reference

19 September 2017

Atsushi Horiike

4

1 reference

19 September 2017

Tomohide Tamura

5

1 reference

19 September 2017

publication date

29 April 2010

1 reference

Japanese Journal of Clinical Oncology

19 September 2017

published in

1 reference

19 September 2017

volume

40

1 reference

19 September 2017

issue

8

1 reference

19 September 2017

page(s)

732-738

1 reference

Control of p70 s6 kinase by kinase activity of FRAP in vivo

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ047

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYQ047

1 reference

19 September 2017

1 reference